

# Ki Hyeong Lee

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6142744/publications.pdf>

Version: 2024-02-01

121  
papers

21,621  
citations

76196

40  
h-index

26548

107  
g-index

121  
all docs

121  
docs citations

121  
times ranked

14871  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 113-125.  | 13.9 | 3,530     |
| 2  | Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations. <i>Journal of Clinical Oncology</i> , 2013, 31, 3327-3334.   | 0.8  | 2,854     |
| 3  | Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 2040-2051.  | 13.9 | 2,676     |
| 4  | Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. <i>New England Journal of Medicine</i> , 2020, 382, 41-50.  | 13.9 | 1,725     |
| 5  | Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. <i>Lancet Oncology</i> , The, 2015, 16, 141-151. | 5.1  | 1,369     |
| 6  | Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. <i>Lancet Oncology</i> , The, 2016, 17, 577-589.         | 5.1  | 950       |
| 7  | Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1454-1466.              | 5.1  | 877       |
| 8  | Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 2027-2039.  | 13.9 | 691       |
| 9  | CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 3290-3297.  | 0.8  | 515       |
| 10 | Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020, 6, 661.  | 3.4  | 446       |
| 11 | Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1301-1311.   | 0.8  | 445       |
| 12 | Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1655-1669.              | 5.1  | 418       |
| 13 | Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 897-907.               | 5.1  | 389       |
| 14 | Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. <i>Journal of Clinical Oncology</i> , 2018, 36, 2244-2250.    | 0.8  | 361       |
| 15 | Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 288-293.   | 0.5  | 328       |
| 16 | Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3391-3402.                      | 0.8  | 320       |
| 17 | Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3449-3457.   | 0.8  | 311       |
| 18 | Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement. <i>Journal of Clinical Oncology</i> , 2017, 35, 2613-2618.  | 0.8  | 260       |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-“Naive ALK-Positive Non-“Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 3592-3603.   | 0.8 | 224       |
| 20 | Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9503-9503. | 0.8 | 179       |
| 21 | First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. <i>Journal of Thoracic Oncology</i> , 2022, 17, 289-308.  | 0.5 | 173       |
| 22 | Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-“small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial. <i>European Journal of Cancer</i> , 2019, 116, 137-147.  | 1.3 | 167       |
| 23 | Brigatinib Versus Crizotinib in ALK Inhibitor-“Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2091-2108.   | 0.5 | 156       |
| 24 | Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. <i>Lancet Oncology</i> , The, 2022, 23, 781-792.                            | 5.1 | 150       |
| 25 | Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2019, 20, 1670-1680.   | 5.1 | 125       |
| 26 | Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- $\beta$ 2 and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1210-1222.  | 0.5 | 119       |
| 27 | Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-“Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2021, 7, 1351.   | 3.4 | 113       |
| 28 | Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-“2 study. <i>Lancet Oncology</i> , The, 2019, 20, 1681-1690.   | 5.1 | 92        |
| 29 | Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset. <i>Journal of Thoracic Oncology</i> , 2019, 14, 99-106.   | 0.5 | 82        |
| 30 | LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.. <i>Journal of Clinical Oncology</i> , 2012, 30, LBA7500-LBA7500.                       | 0.8 | 74        |
| 31 | JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9009-9009.  | 0.8 | 74        |
| 32 | LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.. <i>Journal of Clinical Oncology</i> , 2012, 30, LBA7500-LBA7500.                       | 0.8 | 60        |
| 33 | Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. <i>Drugs</i> , 2021, 81, 257-266.  | 4.9 | 57        |
| 34 | Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials. <i>Clinical Lung Cancer</i> , 2018, 19, e465-e479.  | 1.1 | 56        |
| 35 | Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9512-9512.  | 0.8 | 54        |
| 36 | Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma. <i>JAMA Oncology</i> , 2018, 4, 1189.   | 3.4 | 53        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial. <i>International Journal of Cancer</i> , 2018, 143, 3240-3247.  | 2.3 | 46        |
| 38 | Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01). <i>Cancer</i> , 2017, 123, 1958-1964.  | 2.0 | 44        |
| 39 | Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2017, 49, 1001-1011.   | 1.3 | 43        |
| 40 | A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2022, 17, 558-567.   | 0.5 | 43        |
| 41 | TOX-expressing terminally exhausted tumor-infiltrating CD8+ T cells are reinvigorated by co-blockade of PD-1 and TIGIT in bladder cancer. <i>Cancer Letters</i> , 2021, 499, 137-147.   | 3.2 | 42        |
| 42 | Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9500-9500.   | 0.8 | 42        |
| 43 | Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non-small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 992-1002.  | 3.2 | 36        |
| 44 | A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (<i>EGFR</i>)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR Tyrosine Kinase Inhibitors. <i>Cancer Research and Treatment</i> , 2017, 49, 10-19.  | 1.3 | 35        |
| 45 | EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors. <i>Cancer Research and Treatment</i> , 2018, 50, 908-916.  | 1.3 | 32        |
| 46 | Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07). <i>British Journal of Cancer</i> , 2018, 118, 648-653.   | 2.9 | 31        |
| 47 | First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1569-1579. | 1.2 | 31        |
| 48 | Therapeutic effect of anti CEACAM6 monoclonal antibody against lung adenocarcinoma by enhancing anoikis sensitivity. <i>Biomaterials</i> , 2015, 67, 32-41.   | 5.7 | 29        |
| 49 | Diagnostic benefits of the combined use of liquid-based cytology, cell block, and carcinoembryonic antigen immunocytochemistry in malignant pleural effusion. <i>Journal of Thoracic Disease</i> , 2018, 10, 4931-4939.   | 0.6 | 29        |
| 50 | Updated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine kinase inhibitor (TKI).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8084-8084.   | 0.8 | 28        |
| 51 | Prevalence of and factors associated with anxiety and depression in Korean patients with newly diagnosed advanced gastrointestinal cancer. <i>Korean Journal of Internal Medicine</i> , 2018, 33, 585-594.  | 0.7 | 28        |
| 52 | Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 2795-2805.  | 1.1 | 27        |
| 53 | BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M+ NSCLC: Efficacy and safety at the RP2D.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9055-9055.  | 0.8 | 27        |
| 54 | First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials. <i>Lung Cancer</i> , 2019, 133, 10-19.  | 0.9 | 25        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | Exosomal miR-181b-5p Downregulation in Ascites Serves as a Potential Diagnostic Biomarker for Gastric Cancer-associated Malignant Ascites. <i>Journal of Gastric Cancer</i> , 2019, 19, 301.   | 0.9 | 24        |
| 56 | Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer. <i>European Journal of Cancer</i> , 2017, 86, 385-393.   | 1.3 | 23        |
| 57 | Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 119-127.   | 1.3 | 23        |
| 58 | Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy. <i>Lung Cancer</i> , 2018, 122, 234-242.   | 0.9 | 22        |
| 59 | Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial. <i>Lung Cancer</i> , 2019, 135, 66-72.  | 0.9 | 22        |
| 60 | A Prospective Multicenter Study Evaluating Secondary Adrenal Suppression After Antiemetic Dexamethasone Therapy in Cancer Patients Receiving Chemotherapy: A Korean South West Oncology Group Study. <i>Oncologist</i> , 2015, 20, 1432-1439.  | 1.9 | 21        |
| 61 | Feasibility and accessibility of electronic patient-reported outcome measures using a smartphone during routine chemotherapy: a pilot study. <i>Supportive Care in Cancer</i> , 2018, 26, 3721-3728.   | 1.0 | 21        |
| 62 | Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, LBA9007-LBA9007.   | 0.8 | 21        |
| 63 | Blood tumor mutational burden (bTMB) and tumor PD-L1 as predictive biomarkers of survival in MYSTIC: First-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic (m) NSCLC.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9016-9016.  | 0.8 | 20        |
| 64 | A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09. <i>Supportive Care in Cancer</i> , 2016, 24, 1709-1717.  | 1.0 | 19        |
| 65 | Diagnostic performance of CD66c in lung adenocarcinoma-associated malignant pleural effusion: comparison with CEA, CA 19-9, and CYFRA 21-1. <i>Pathology</i> , 2015, 47, 123-129.  | 0.3 | 18        |
| 66 | Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050). <i>Lung Cancer</i> , 2021, 154, 176-185.   | 0.9 | 18        |
| 67 | Two-year update from KEYNOTE-799: Pembrolizumab plus concurrent chemoradiation therapy (cCRT) for unresectable, locally advanced, stage III NSCLC.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8508-8508.   | 0.8 | 16        |
| 68 | Phase II study of pembrolizumab (pembro) plus platinum doublet chemotherapy and radiotherapy as first-line therapy for unresectable, locally advanced stage III NSCLC: KEYNOTE-799.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9008-9008.  | 0.8 | 15        |
| 69 | Molecular Screening of Small Biopsy Samples Using Next-Generation Sequencing in Korean Patients with Advanced Non-small Cell Lung Cancer: Korean Lung Cancer Consortium (KLCC-13-01). <i>Journal of Pathology and Translational Medicine</i> , 2018, 52, 148-156.  | 0.4 | 15        |
| 70 | Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients. <i>International Journal of Cancer</i> , 2019, 145, 1669-1678. | 2.3 | 14        |
| 71 | Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2022, 23, 214-225.  | 1.1 | 14        |
| 72 | KEYNOTE-799: Phase 2 trial of pembrolizumab plus platinum chemotherapy and radiotherapy for unresectable, locally advanced, stage 3 NSCLC.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8512-8512.   | 0.8 | 13        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 73 | A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01). <i>Oncotarget</i> , 2017, 8, 15943-15951.   | 0.8 | 11        |
| 74 | Do health literacy and self-care behaviours affect quality of life in older persons with lung cancer receiving chemotherapy?. <i>International Journal of Nursing Practice</i> , 2018, 24, e12691.   | 0.8 | 11        |
| 75 | First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm+) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9046-9046.   | 0.8 | 11        |
| 76 | Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC). <i>Clinical Lung Cancer</i> , 2021, 22, 301-312.e8.   | 1.1 | 10        |
| 77 | Results from a second-line (2L) NSCLC cohort treated with M7824 (MSB0011359C), a bifunctional fusion protein targeting TGF- $\beta$ 2 and PD-L1.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9017-9017.   | 0.8 | 10        |
| 78 | A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13. <i>Cancer Research and Treatment</i> , 2019, 51, 718-726. | 1.3 | 10        |
| 79 | Real World Experience of Nivolumab in Non-Small Cell Lung Cancer in Korea. <i>Cancer Research and Treatment</i> , 2020, 52, 1112-1119.   | 1.3 | 10        |
| 80 | Pseudoprogression presenting as intestinal perforation in non-small cell lung cancer treated with anti-PD-1: A case report. <i>Molecular and Clinical Oncology</i> , 2019, 11, 132-134.  | 0.4 | 9         |
| 81 | E7080 (lenvatinib) in addition to best supportive care (BSC) versus BSC alone in third-line or greater nonsquamous, non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8043-8043.  | 0.8 | 9         |
| 82 | Dacomitinib (daco) versus gefitinib (gef) for first-line treatment of advanced NSCLC (ARCHER 1050): Final overall survival (OS) analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9004-9004.  | 0.8 | 9         |
| 83 | The Effect of Disability on the Diagnosis and Treatment of Multiple Myeloma in Korea: A National Cohort Study. <i>Cancer Research and Treatment</i> , 2020, 52, 1-9.   | 1.3 | 9         |
| 84 | Differences in diagnosis, treatment, and survival rate of acute myeloid leukemia with or without disabilities: A national cohort study in the Republic of Korea. <i>Cancer Medicine</i> , 2020, 9, 5335-5344.  | 1.3 | 7         |
| 85 | Two-year follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF- $\beta$ 2 and PD-L1, for second-line (2L) treatment of non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9558-9558.   | 0.8 | 7         |
| 86 | Cardiac Safety Assessment of Lazertinib: Findings From Patients With EGFR Mutation-Positive Advanced NSCLC and Preclinical Studies. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100224.  | 0.6 | 6         |
| 87 | PEARLY: A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo)adjuvant therapy in patients with early triple-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS587-TPS587.  | 0.8 | 6         |
| 88 | Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG) Tj ETQq0 0 0 rgt / Overlock 10 T   | 3.7 | 5         |
| 89 | E-Cadherin and Angiopoietin-2 as Potential Biomarkers for Colorectal Cancer With Peritoneal Carcinomatosis. <i>Anticancer Research</i> , 2021, 41, 4497-4504.  | 0.5 | 5         |
| 90 | Histologic Changes in Non-Small Cell Lung Cancer Under Various Treatments: A Comparison of Histology and Mutation Status in Serial Samples. <i>Cancer Research and Treatment</i> , 2021, , .   | 1.3 | 5         |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 91  | First-in-human study of HM95573, a novel oral RAF inhibitor, in patients with solid tumors.. Journal of Clinical Oncology, 2016, 34, 2570-2570.  | 0.8 | 4         |
| 92  | Efficacy and safety results of ramucirumab in combination with osimertinib in advanced T790M-positive EGFR-mutant NSCLC.. Journal of Clinical Oncology, 2018, 36, 9053-9053.   | 0.8 | 4         |
| 93  | A Case of Acquired Amegakaryocytic Thrombocytopenia with Anti-c-mpl Autoantibody: Comparison with Idiopathic Thrombocytopenic Purpura. Acta Haematologica, 2019, 142, 239-243.   | 0.7 | 3         |
| 94  | Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors. JTO Clinical and Research Reports, 2021, 2, 100206.  | 0.6 | 3         |
| 95  | Phase II trial of nintedanib in patients with recurrent or metastatic salivary gland cancer: A multicenter phase II study.. Journal of Clinical Oncology, 2016, 34, 6090-6090.   | 0.8 | 3         |
| 96  | Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial.. Journal of Clinical Oncology, 2017, 35, LBA9007-LBA9007.   | 0.8 | 3         |
| 97  | Diagnostic Value of Ascitic Tumor Markers for Gastric Cancer-associated Malignant Ascites. The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2022, 22, 38-49.  | 0.1 | 3         |
| 98  | A Case of Superwarfarin Intoxication without a Definitive History of Brodifacoum Exposure. The Korean Journal of Hematology, 2009, 44, 53.   | 0.7 | 2         |
| 99  | 18F-fluorodeoxyglucose positron emission tomography/computed tomography findings in descending necrotizing mediastinitis and cervical vertebral osteomyelitis in a cancer patient. Medicine (United States), 2014, 93, 14.   | 0.7 | 2         |
| 100 | YH25448, a 3rd generation EGFR-TKI, in patients with EGFR-TKI-resistant NSCLC: Phase I/II study results.. Journal of Clinical Oncology, 2018, 36, 9033-9033.   | 0.8 | 2         |
| 101 | Patient-reported outcomes (PROs) with first-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic NSCLC: Results from MYSTIC.. Journal of Clinical Oncology, 2019, 37, 9048-9048.  | 0.8 | 2         |
| 102 | A phase III, open-label, randomized study of atezolizumab in combination with carboplatin + paclitaxel + bevacizumab compared with pemetrexed + cisplatin or carboplatin with stage IV non-squamous non-small cell lung cancer (NSCLC) with activating EGFR mutation or ALK translocation (ATLAS Trial).. Journal of Clinical Oncology, 2020, 38, TPS9636-TPS9636. | 0.8 | 2         |
| 103 | 363 Vactosertib and durvalumab as second or later line treatment for PD-L1 positive non-small cell lung cancer: interim result. , 2020, , .  |     | 2         |
| 104 | Impact of the availability of active cytotoxic agents on the survival of patients with advanced gastric cancer. Oncology Letters, 2015, 10, 2481-2486.   | 0.8 | 1         |
| 105 | A randomized, open label, phase II study comparing pemetrexed plus cisplatin followed by pemetrexed versus pemetrexed alone in EGFR mutant NSCLC patients who have failed first-line EGFR TKI: KCSG-LU12-13.. Journal of Clinical Oncology, 2016, 34, 9043-9043.   | 0.8 | 1         |
| 106 | Role of HER2 copy number amplification and PI3K pathway as a biomarker for patients with HER2+ MBC treating with Pozitotinib, pan-HER TKI.. Journal of Clinical Oncology, 2018, 36, e13009-e13009.   | 0.8 | 1         |
| 107 | ctDNA resistance landscape of lazertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI).. Journal of Clinical Oncology, 2020, 38, 9601-9601.   | 0.8 | 1         |
| 108 | Open-label, multicenter, randomized phase III trial of pemetrexed/carboplatin doublet vs pemetrexed singlet in chemotherapy-naïve elderly patients aged 70 or more with advanced non-squamous non-small cell lung cancer and good performance status.. Journal of Clinical Oncology, 2016, 34, 9081-9081.  | 0.8 | 1         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 109 | A phase II, multicenter, randomized trial of eribulin plus gemcitabine (EG) vs. paclitaxel plus gemcitabine (PG) in patients with HER2-negative metastatic breast cancer (MBC) as first-line chemotherapy (KCSG BR13-11, NCT02263495).. Journal of Clinical Oncology, 2017, 35, 1082-1082.  | 0.8 | 1         |
| 110 | Long-term Survival after Repeated Local Therapy and Salvage Chemotherapy for Recurrent Metastases from Gastric Cancer: a Case Report and Literature Review. Journal of Gastric Cancer, 2018, 18, 305.   | 0.9 | 0         |
| 111 | The patientâ€™s perspective on treatment with dacomitinib: patient-reported outcomes from the Phase III trial ARCHER 1050. Future Oncology, 2021, 17, 783-794.  | 1.1 | 0         |
| 112 | Comparison of Bleeding, Hematoma, Pain, and Discomfort After Bone Marrow Examination With or Without Sandbag Compression. Asian Nursing Research, 2021, 15, 150-156.  | 0.7 | 0         |
| 113 | Multicenter phase II study of docetaxel and oxaliplatin combination in patients with locally advanced or metastatic biliary tract cancer.. Journal of Clinical Oncology, 2014, 32, e15150-e15150.   | 0.8 | 0         |
| 114 | A phase II, single-arm, efficacy and safety study of poziotinib (NOV120101) in Korean patients with advanced or metastatic lung adenocarcinoma who have acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors.. Journal of Clinical Oncology, 2015, 33, 8085-8085.   | 0.8 | 0         |
| 115 | Prevalence and associated factors of anxiety and depression in patients with metastatic gastrointestinal cancer.. Journal of Clinical Oncology, 2015, 33, e20718-e20718.  | 0.8 | 0         |
| 116 | Prospective multicenter study evaluating adrenal suppression after dexamethasone therapy as an antiemetic in cancer patients: a KSWOG (Korean South West Oncology Group) study.. Journal of Clinical Oncology, 2015, 33, 9605-9605.   | 0.8 | 0         |
| 117 | Phase II study of nivolumab in patients with advanced non-small cell lung cancer (NSCLC) in Korea.. Journal of Clinical Oncology, 2017, 35, 92-92.  | 0.8 | 0         |
| 118 | Quality of life(QoL) outcomes including neuropathy associated scale (FACT-T) from a phase II, multicenter, randomized trial of eribulin plus gemcitabine(EG) versus paclitaxel plus gemcitabine(PG) as first-line chemotherapy for human epidermal growth factor receptor 2 (HER2)- negative metastatic breast cancer(MBC): Korean Cancer Study Group trial (KCSG BR13-11).. Journal of Clinical Oncology, 2018, 36, 10117-10117. | 0.8 | 0         |
| 119 | Abstract P1-16-01: Pemetrexed plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer: A randomized, open-label, multicenter, phase II trial (KCSG-BR15-17). Cancer Research, 2022, 82, P1-16-01-P1-16-01.  | 0.4 | 0         |
| 120 | Association of depth of target lesion response to brigatinib with outcomes in patients with ALK inhibitor-naïve <i>ALK+</i> NSCLC in ALTA-1L.. Journal of Clinical Oncology, 2022, 40, 9072-9072.   | 0.8 | 0         |
| 121 | A randomized phase II study comparing erlotinib with or without bevacizumab in patients with advanced nonâ€™small cell lung cancer (NSCLC) with <i>EGFR</i> mutation.. Journal of Clinical Oncology, 2022, 40, 9107-9107.   | 0.8 | 0         |